People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS2026).
This article was originally published on MedicalXpress.com

